Treace Announces Participation in the Morgan Stanley 19th Annual Global Healthcare Conference

PONTE VEDRA, Fla., Sept. 02, 2021 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace”) (Nasdaq: TMCI), a commercial-stage orthopaedic medical device company driving a paradigm shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced that John T. Treace, Chief Executive Officer, and Mark Hair, Chief Financial Officer, will participate in a virtual fireside chat at the Morgan Stanley 19^th Annual Global Healthcare Conference on Tuesday, September 14, 2021, beginning at approximately 4:15 pm ET.

A live webcast and replay of the fireside chat will be available on the Company’s investors relations website at https://investors.treace.com/.

About Treace Medical Concepts
Treace Medical Concepts, Inc. is a commercial-stage orthopaedic medical device company with the goal of advancing the standard of care for the surgical management of bunion deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction™ system – a combination of instruments, implants, and surgical methods designed to correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and getting patients back to their active lives quickly.

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
[email protected]
(904) 373-5940

Investors:
Gilmartin Group
Lynn Lewis or Vivian Cervantes
[email protected]